• Vk
  • LinkedIn
  • Youtube
X7 Research
  • News
  • Registration strategy and Сonsulting
    • Budgeting
    • Registration strategy development
    • Study feasibility
    • Vendor selection
    • Data search and analysis
  • Clinical trials
    • Outsourcing CRAs in Russia and the EAEU
    • Development of medical documentation and biostatistics
    • Monitoring
    • Data-management
    • Patient home visits
    • Bioequivalence study
    • Therapeutic equivalence studies
    • Clinical trials of medical devices
  • Registration
    • Audit of the registration dossier
    • Bringing the registration dossier in compliance with the requirements of the EAEU
    • Conversion of registration dossier into XML format
    • PIL readability user testing
    • Translation of the Registration dossier
    • Turnkey registration
  • Post-authorization clinical studies
    • Phase IV studies
    • Non-interventional studies
    • Investigator-initiated studies
    • Post-authorisation safety study
    • Marketing research
  • Pharmacovigilance
    • QPPV in the EAEU
    • Safety monitoring of medical devices
    • Building a pharmacovigilance system
    • Safety in clinical trials
    • Pharmacovigilance audit
    • Pharmacovigilance contact person
  • Therapeutic expertise
    • Clinical trials in Oncology in the EAEU
  • Contact
  • EnglishEnglish
    • РусскийРусский
  • Menu

Drug is finally approved? It’s not over yet.

25.05.2017/in News /by eugeneqqq

Successful approval does not always guarantee unconditional and easy profit for pharma industry. US FDA approved 222 novel therapeutics through 2001 to 2010. Among them, 183 (82,4%) were pharmaceuticals and 39 (17,6%) were biologics. But many of those approvals faced safety issues during the postmarket period.

A cohort study of all novel therapeutics approved by the FDA between January 1, 2001, and December 31, 2010, (followed up through February 28, 2017) revealed that among these novel therapeutics 71 (32,0%) were affected by postmarket safety events.
Downing et al. (article published in JAMA) conducted a study to examine risk factors for postmarket safety events occurrence among novel therapeutics and frequency of such events.

During the median follow-up of 11,7 years, there were 3 withdrawals due to safety concerns: Pimecrolimus (calcineurin inhibitor) for atopic dermatitis due to skin cancer risk, Efalizumab – (monoclonal antibody against lymphocyte receptor CD11a) for psoriasis due to high risk of systemic infection and Tegaserod (5-HT4 agonist) for management of irritable bowel syndrome due to high cardiovascular events risk.
FDA issuance of incremental boxed warnings added in the postmarket period – a measure used to indicate that potentially life-threatening or preventable safety events had been observed in the postmarket period affected 43 novel therapeutics during the follow-up.

Also, there were 59 FDA safety communications during the study period.
Study identified several risk factors associated with increased frequency of postmarket safety events. Biologics were at higher risk compared with pharmaceuticals. Psychiatric Therapeutics were at the highest risk for safety events occurrence. Several other patterns were identified in the study.

The authors came to an obvious conclusion that postmarket safety monitoring should be continued at least to the same extent. The results that are most important for industry concern special regulatory approval pathways. Most interestingly, priority review and orphan status were not associated with postmarket safety events. Even though, accelerated approval and near-regulatory deadline approval were significant risk factors for safety event occurrence.
Thus, some special regulatory pathways turned out to be safer than others. The pharmaceutical industry should keep this exact conclusion in mind to maximize the cost-effectiveness of drug development and manufacturing.

Share this entry
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

YOU MAY ALSO BE INTERESTED IN

Publications
Readability User Testing of Package Information Leaflets (PIL) in EAEU
Read More
Publications
Remote clinical trial monitoring
Read More
Publications
Post-authorization studies of drug safety in Russia
Read More

RUBRICS

Registration strategy and Сonsulting

Clinical trials

Registration

Post-authorization clinical studies

Pharmacovigilance

LATEST PUBLICATIONS

  • Corrections to clinical trial documents due to COVID-19. Russian experience.
  • WHAT IS BIOEQUIVALENCE
  • THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019

Tags

bioequivalenceClinical trials in the CISfeasibilitymonitoringRadiopharmaceuticals

CONTACT

2 + 5 = ?

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

PRIVACY

Use of this site constitutes your consent to our Privacy Policy.


SOCIAL RESPONSIBILITY

X7 Research’s primary responsibility is to help our clients in bringing medicines & products to the market efficiently and safely.

The Best CRO for Clinical Trials | Full-service Global CRO — X7 Research

The Best CRO in Pharma | Clinical Research Organisation — X7 Research

The Best Contract Research Organisation (CRO) | Trusted CRO — X7 Research

The Best Clinical Research Organisation (CRO): Full Service CRO | X7 Research

The Best CRO in Research | Trusted CRO for Your Trail — X7 Research

The Best Clinical Trial Company | Global Full-service CRO - X7 Research

The Best Pharma CROs: Clinical Trials for Drugs | X7 Research

The Best CROs Company: Clinical Trials with Global CRO — X7 Research

The Best Pre-clinical CRO: Safety Assessment With X7 Research

The Best Clinical Development | Trusted CRO for Your Product: X7 Research

The Best Biostatistical Consulting: Statistical Services | X7 Research

The Best Pharmacovigilance Consulting Services | CRO — X7 Research

Feasibility in Clinical Trials: What is a Feasibility in Clinical Trials?

Clinical Study Trials: What are Clinical Study Trials?

Category
Strategy and consulting
Clinical trials
Registration
Post-authorization clinical studies
Pharmacovigilance

Registration strategy and Сonsulting
Registration strategy development
Budgeting
Study feasibility
Vendor selection
Data search and analysis

Clinical trials
Development of medical documentation and biostatistics
Monitoring
Data management
Patient home visits
Bioequivalence study
Therapeutic equivalence studies

Registration
Audit of the registration dossier
Dossier eaeu
Conversion of registration dossier into xml format
Pil readability user testing
Turnkey registration

Post-authorization clinical studies
Phase iv studies
Non interventional studies
Investigator initiated studies
Post authorisation safety study
Marketing research

Pharmacovigilance
Building a pharmacovigilance system
Safety in clinical trials
Pharmacovigilance audit
Pharmacovigilance contact person

Blog
Contacts

© Copyright 2010-2023 - X7 Research. All rights reserved.
Treating cerebral palsy with game addiction Keytruda – a new hope for oncology.
Scroll to top